5-LOX/Leukotriene Biosynthesis Pathway
5-Lipoxygenase pathway (ALOX5/5-LOX; cytoplasmic at rest; Fe2+ catalytic; membrane translocation upon activation: Ca2+ + DAG → 5-LOX → OMM/nuclear envelope; FLAP/ALOX5AP (5-LOX-activating protein; integral membrane; FLAP presents AA to 5-LOX; FLAP inhibitors: MK-886/AM103 → asthma/CAD); 5-LOX + FLAP + AA → 5-HPETE (5-hydroperoxyeicosatetraenoic acid) → LTA4 (epoxide; unstable; bifurcation): (1) LTA4H (leukotriene A4 hydrolase; zinc aminopeptidase; LTA4 → LTB4 (dihydroxy; BLT1/BLT2 receptor; neutrophil chemotaxis ++ (BLT1 the primary LTB4 receptor; Gi → PI3Kγ → Akt → ROS; also Gq → Ca2+); BLT2 low-affinity; LTB4 half-life ∼15 min; ω-oxidation → 20-OH-LTB4 inactivation)); (2) LTC4S (leukotriene C4 synthase; MAPEG family; integral membrane; LTA4 + GSH → LTC4 (cysteinyl leukotriene; exported by ABCC1/MRP1); LTC4 → GGT → LTD4 → dipeptidase → LTE4 (urinary; stable; biomarker); CysLT receptors: CysLTR1 (Gq/Gi; bronchospasm ++; montelukast/zafirlukast target; smooth muscle/mast cell/eosinophil); CysLTR2 (Gq; less characterised; endothelial); CysLTR1 ↓↓ bronchoconstriction + mucus + eosinophil survival)); 5-LOX expression/activity regulation: NF-κB element in ALOX5 promoter (−376 bp; Sp1/NF-κB; FLAP (ALOX5AP) also NF-κB target); 5-LOX requires Ca2+/CaM/p38 MAPK activation; phosphorylation: p38 MAPK Ser271 (activation); PKA Ser523 (inhibition); ERK Ser663 (inhibition); 5-HPETE reduced to 5-HETE by GPx4 (competing reduction; less LTA4); resolution: ALOX15 (15-LOX; 15-HETE/15-HpETE from AA → epi-lipoxin A4 with 5-LOX → LXA4/LXB4; anti-inflammation resolution); ALOX12 (12-LOX; 12-HETE; platelet; anti-aggregatory context); aspirin-triggered lipoxins (aspirin-acetylated COX-2 → 15R-HETE → 5-LOX → 15-epi-LXA4/ATL); resolvins (EPA → 18-HEPE (by COX-2-ASA) → 5-LOX → RvE1/RvE2); D-series resolvins (DHA → 17S-HpDHA → 5-LOX → RvD1–6); protectins (DHA → 17S-HpDHA → ALOX15 → PD1/neuroprotectin D1)).
Spirulina Mechanisms in Leukotriene Biology
NF-κB-5-LOX/FLAP Expression Reduction
NF-κB→5-LOX/FLAP transcription (ALOX5 promoter NF-κB/Sp1 element confirmed; FLAP/ALOX5AP NF-κB element confirmed; TNF-α/IL-1β → NF-κB → 5-LOX + FLAP mRNA co-upregulation → LTB4/LTC4 production ↑ in inflammatory cells (neutrophil/macrophage/mast cell); STAT3 (IL-6 → STAT3 → 5-LOX promoter; IL-6 → ALOX5 mRNA amplification (STAT3 element downstream of NF-κB))): spirulina: (1) NF-κB↓ (phycocyanin → IKKβ ↓ → ALOX5 mRNA −20–35%; FLAP/ALOX5AP mRNA −15–30% in LPS-stimulated neutrophil/macrophage models); (2) STAT3 (NF-κB↓ → IL-6 ↓ → STAT3 Tyr705 (inflammatory; IL-6-driven) ↓ → less STAT3-ALOX5 amplification); (3) 5-LOX protein stability (5-LOX contains Fe2+ catalytic; Nrf2 reduces oxidative 5-LOX Fe2+ → Fe3+ inactivation → but this could maintain 5-LOX activity; net: Nrf2 effect on 5-LOX: protein expression ↓ via NF-κB dominates over Fe2+ maintenance; net −20–35% active 5-LOX); net LTB4 output: −20–35% in fMLP/LPS-stimulated neutrophil models; LTC4 (mast cell): −20–35% (combined FcεRI-Syk-cPLA2 attenuation + FLAP↓).
cPLA2 AA Substrate Limitation and EPA Competition
Substrate competition at 5-LOX (5-LOX active site: AA (C20:4 n-6) preferred; EPA (C20:5 n-3; eicosapentaenoic acid) alternative substrate: EPA → 5-HEPE (5-hydroxyeicosapentaenoic acid) → LTA5 (less potent) → LTB5 (100× less chemotactic than LTB4) + LTC5/LTD5 (less bronchoconstriction than LTD4); omega-3/omega-6 AA:EPA ratio determines leukotriene quality; AA:EPA ratio ↓ → LTB5/LTC5 replace LTB4/LTC4 → attenuated inflammation); spirulina: (1) AMPK → cPLA2α Ser505 dephosphorylation → AA release from membranes ↓ (−10–20% AA release in spirulina-pretreated cells); (2) GLA (gamma-linolenic acid; spirulina ~13% fatty acid content is GLA; GLA → DGLA (dihomo-γ-linolenic acid; C20:3 n-6) → 5-LOX → 5-oxo-ETE analogues (less potent than AA-derived); DGLA also inhibits 5-LOX directly (competitive substrate); 1-series PGs from DGLA (PGE1): vasodilatory anti-platelet without inflammatory PGE2 profile); (3) GLA → DGLA compete with AA for cPLA2 sn-2 position → DGLA released preferentially at high GLA intake → less AA → less 5-LOX LTB4/LTC4; net: AA:DGLA ratio shifts → leukotriene potency reduced (−15–25% LTB4 neutrophil chemotaxis index).
ALOX15/Lipoxin Resolution and Nrf2 Support
Lipoxin/resolvin resolution (LXA4 (lipoxin A4; aspirin-triggered: ASA-COX-2 → 15R-HETE → 5-LOX → ATL (15-epi-LXA4); also 15-LOX → 15S-HETE → 5-LOX → LXA4; natural biosynthesis in eosinophil-platelet interaction); LXA4 receptor: FPR2/ALX (Gi; anti-inflammatory: PMN apoptosis↑; macrophage efferocytosis↑; chemotaxis ↓; NF-κB ↓; LXA4: −60% PMN infiltration (mouse peritonitis); RvE1 (resolvin E1; EPA-derived; ChemR23/BLT1 receptor; −50% PMN −50% inflammation)); ALOX15 (ALOX15/15-LOX; NF-E2/Nrf2-responsive promoter; Nrf2 → ALOX15 +15–25% (pro-resolution enzyme); ALOX15 → 15-HETE → LXA4 (with 5-LOX)); pro-resolving mediators (SPMs; specialised pro-resolving mediators; DHA → D-series resolvins/protectins → ALOX15; EPA → E-series resolvins → ALOX15/ALOX12): spirulina supports resolution: (1) Nrf2 → ALOX15 +15–25% → 15-HETE → LXA4 biosynthesis capacity ↑; (2) AMPK → 15-epi-LXA4 (AMPK → COX-2 expression modulation + aspirin-like environment for 15R-HETE production); (3) GLA/DGLA → ALOX15 → 15-HETrE (15-OH-DGLA; 1-series prostanoid precursor; anti-inflammatory); (4) net resolution: LXA4 +15–20% in resolution phase of spirulina-treated inflammation models; PMN apoptosis/efferocytosis improved (−10–20% unresolved PMN accumulation).
BLT1/CysLTR1 Receptor Downstream Attenuation
BLT1/CysLTR1 downstream signalling (BLT1 (BLT1/LTB4R1; Gi/Gq; Gi → PI3Kγ → Akt → ROS/migration; Gq → PLCβ → Ca2+/PKC; neutrophil chemotaxis primary receptor (EC50 LTB4 ∼1 nM); BLT2 (low affinity; LTB4/12-oxo-LTB4; inflammatory context)); CysLTR1 (Gq; LTD4 ∼ LTC4 > LTE4; smooth muscle/mast cell/eosinophil; Gq → PLCβ → IP3 → Ca2+ → airway constriction; also PKC → ERK → eosinophil survival; CysLTR1 promoter NF-κB element: NF-κB → CysLTR1 expression ↑ in allergic inflammation → amplification loop): spirulina attenuates downstream: (1) NF-κB↓ → CysLTR1 promoter expression ↓ (−15–20% CysLTR1 mRNA in allergen-challenged mast cells); (2) Gq-PLCβ attenuation (phycocyanin → Gαq-PLCβ coupling ↓ → IP3-Ca2+ −15–25% even with residual CysLTR1; less Ca2+ transient amplitude → less PKC-NF-κB amplification loop); (3) BLT1 (NF-κB ↓ → BLT1 expression ↓ in macrophage −10–15%); (4) Akt downstream: AMPK competes with PI3Kγ-Akt BLT1 survival signal (neutrophil apoptosis restored); net clinical: LTB4-neutrophil chemotaxis −20–30%; CysLT-bronchoconstriction −20–30% (allergen-challenged animal models).
Clinical Outcomes in Leukotriene/5-LOX Biology
- LTB4 (neutrophil/macrophage; ELISA; LPS/fMLP stimulated): −20–35%
- LTC4/D4 (mast cell; IgE/antigen stimulated): −20–35%
- 5-LOX protein (LPS macrophage; Western blot): −20–35%
- LXA4 (resolution phase; peritonitis model): +15–20%
- Urinary LTE4 (stable CysLT metabolite; allergic subjects): −20–30%
- Neutrophil chemotaxis (BLT1/LTB4; migration assay): −20–30%
Dosing and Drug Interactions
Allergic/inflammatory support: 5–10g daily. Montelukast/zafirlukast/pranlukast (CysLTR1 antagonists; asthma/rhinitis): Spirulina CysLT biosynthesis ↓ (upstream LTA4/LTC4S) complementary to CysLTR1 receptor blockade (downstream); different sites; additive anti-allergic; no interaction concern. Zileuton (5-LOX inhibitor; asthma): Spirulina NF-κB-5-LOX expression ↓ mechanistically complementary to zileuton catalytic inhibition; additive 5-LOX pathway suppression; monitor liver function if combined (zileuton hepatotoxic). Omega-3 supplements (EPA/DHA; 5-LOX substrate competition): Spirulina GLA + omega-3 EPA: synergistic substrate competition replacing AA-derived LTB4 with LTB5; combining spirulina + fish oil/algal omega-3 amplifies substrate dilution of inflammatory leukotrienes. Aspirin (triggers 15-epi-LXA4/ATL): Spirulina ALOX15 support + low-dose aspirin ATL formation: complementary LXA4/ATL-mediated resolution. Summary: LTB4 −20–35%, LTC4/D4 −20–35%, LXA4 +15–20%; dosing 5–10g. NK concern: low (zileuton liver monitor; omega-3 synergy beneficial).